Publications: Dr Banu Rudran
Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H et al.
(
2023
)
.
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
The Lancet Diabetes & Endocrinology
vol.
11
,
(
12
)
905
-
914
.
Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H et al.
(
2023
)
.
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
.
The Lancet
vol.
401
,
(
10387
)
1499
-
1507
.
Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H et al.
(
2022
)
.
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
.
The Lancet
vol.
400
,
(
10349
)
359
-
368
.
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al.
(
2022
)
.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
The Lancet
vol.
399
,
(
10325
)
665
-
676
.
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al.
(
2021
)
.
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
The Lancet
vol.
399
,
(
10320
)
143
-
151
.
Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M et al.
(
2021
)
.
Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
.
European Journal of Clinical Microbiology & Infectious Diseases
vol.
40
,
(
9
)
2051
-
2051
.
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA et al.
(
2021
)
.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
.
Intensive Care Medicine
vol.
47
,
(
8
)
867
-
886
.
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al.
(
2021
)
.
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
.
The Lancet
vol.
397
,
(
10289
)
2049
-
2059
.
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N et al.
(
2021
)
.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
The Lancet
vol.
397
,
(
10285
)
1637
-
1645
.
Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, Abdelfattah M, Abdul B et al.
(
2021
)
.
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
.
The Lancet
vol.
397
,
(
10274
)
605
-
612
.
Gramegna A, Sotgiu G, Di Pasquale M, Radovanovic D, Terraneo S, Reyes LF, Vendrell E, Neves J et al.
(
2020
)
.
Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective
.
BMC Infectious Diseases
vol.
20
,
(
1
)
Marin-Corral J, Pascual-Guardia S, Amati F, Aliberti S, Masclans JR, Soni N, Rodriguez A, Sibila O et al.
(
2020
)
.
Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia
.
CHEST Journal
vol.
159
,
(
1
)
58
-
72
.
Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M et al.
(
2020
)
.
Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
.
European Journal of Clinical Microbiology & Infectious Diseases
vol.
39
,
(
8
)
1513
-
1525
.
Logishetty K, Gofton WT, Rudran B, Beaulé PE, Cobb JP
(
2020
)
.
Fully Immersive Virtual Reality for Total Hip Arthroplasty: Objective Measurement of Skills and Transfer of Visuospatial Performance After a Competency-Based Simulation Curriculum
.
Journal of Bone and Joint Surgery
vol.
102
,
(
6
)
Villafuerte D, Aliberti S, Soni NJ, Faverio P, Marcos PJ, Wunderink RG, Rodriguez A, Sibila O et al.
(
2019
)
.
Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
.
Respirology
vol.
25
,
(
5
)
543
-
551
.
Aliberti S, Cook GS, Babu BL, Reyes LF, Rodriguez AH, Sanz F, Soni NJ, Anzueto A et al.
(
2019
)
.
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia
.
Journal of Infection
vol.
79
,
(
4
)
300
-
311
.
Radovanovic D, Sotgiu G, Jankovic M, Mahesh PA, Marcos PJ, Abdalla MI, Di Pasquale MF, Gramegna A et al.
(
2018
)
.
An international perspective on hospitalized patients with viral community-acquired pneumonia
.
European Journal of Internal Medicine
vol.
60
,
54
-
70
.
Carugati M, Aliberti S, Reyes LF, Sadud RF, Irfan M, Prat C, Soni NJ, Faverio P et al.
(
2018
)
.
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study
.
ERJ Open Research
vol.
4
,
(
4
)
00096
-
02018
.
Rudran B, Reader C, Foster J, Hodivala-Dilke K, Sosabowski J, Marshall J
(
2018
)
.
P1.03-19 Antibody Blockade of Integrin Alpha-V-Beta-6 (avb6) as a Novel Treatment for NSCLC
.
Journal of Thoracic Oncology
.
vol.
13
,
s518
-
s519
.
Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, Rupp J, del Castillo JG et al.
(
2018
)
.
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients
.
Clinical Infectious Diseases
vol.
68
,
(
9
)
1482
-
1493
.
Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C et al.
(
2018
)
.
Burden and Risk Factors for Pseudomonas aeruginosa Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients
.
European Respiratory Journal1701190
-
1701190
.
Rudran B, Reader C, Foster J, Hodivala-Dilke K, Sosabowski J, Marshall J
(
2018
)
.
12 Blockade of integrin alpha-v-beta-6 (αvβ6) reduces the invasive potential of NSCLC
.
Lung Cancer
vol.
115
,
s5
-
s6
.
Rudran B, Reader C, Foster J, Hodivala-Dilke K, Sosabowski J, Marshall J
(
2018
)
.
Blockade of integrin alpha-v-beta-6 (αvβ6) reduces the invasive potential of NSCLC
.
LUNG CANCER
.
vol.
115
,
S5
-
S6
.
Rudran B, Desai A, Luzarraga M, Hodivala-Dilke K, Foster J, Sosabowski J, Marshall J
(
2017
)
.
Development of non-invasive imaging of integrin alpha-v-beta-6 (alpha v beta 6)-positive lung cancers in advance of testing alpha v beta 6-targeted therapies
.
Lung Cancer
.
Conference:
British Thoracic Oncology Group Conference 2017
(
Dublin, Ireland
)
from:
25/01/2017
to:
27/01/2017
,
vol.
103
,
S4
-
S4
.
Rudran B, Desai A, Luzarraga M, Hodivala-Dilke K, Foster J, Sosabowski J, Marshall J
(
2017
)
.
6: Development of non-invasive imaging of integrin alpha-v-beta-6 (αvβ6)-positive lung cancers in advance of testing αvβ6-targeted therapies
.
Lung Cancer
vol.
103
,
Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI et al.
(
2016
)
.
Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study
.
The Lancet Infectious Diseases
vol.
16
,
(
12
)
1364
-
1376
.
Rudran B, Marshall JF
(
2015
)
.
7: The integrin αvβ6: a new target for therapy in non-small cell lung cancer
.
Lung Cancer
.
vol.
87
,
Rudran B, Idris L, Childs C, Riccio F, Loganathan S, Shaw TJ
(
2011
)
.
P214 Acute exacerbations of COPD: a review of resuscitation status and associations with prognostic factors in hospital admissions
.
Thorax
.
vol.
66
,
a154
-
a155
.
Shafiq I, Huggett K, Rudran B, Morrison G, Idris L, Shaw T
(
2011
)
.
Use Of COPD Assessment Test (CAT) To Monitor Recovery From An Acute Exacerbation
.
Conference:
C44. COPD: NOVEL DIAGNOSTIC TOOLSa4603
-
a4603
.
Rudran B, Jarvis M, Thomas D, Sanmani L, Ranaweera N, Cook A, George S, Cummin A et al.
(
2011
)
.
HIV testing in acute medical admissions
.
HIV MEDICINE
.
vol.
12
,
62
-
62
.